Biopharmaceutical partner
Appears in 3 stories
Co-development and royalty partner on lonvo-z
On April 27, 2026, Intellia Therapeutics reported results from Phase 3 testing of lonvoguran ziclumeran (lonvo-z), a one-time in-body CRISPR gene-editing therapy for hereditary angioedema. The 80-patient randomized double-blind trial found a single IV infusion cut debilitating swelling attack rates by 87% versus placebo (weeks 5-28); 62% of patients became attack-free and stopped all preventive medications. The safety profile was clean: no serious adverse events, and infusion-related reactions, headache, and fatigue—the most common complaints—were mild or moderate.
Updated May 31
Co-developer and co-marketer of Dupixent; 74% of revenue dependent on key biologic drugs
Dupixent was approved for severe eczema in 2017 as a one-disease drug. Nine years later, it's approved for nine conditions, with the latest approval (February 24, 2026) covering allergic fungal rhinosinusitis (AFRS) — which previously had no approved treatment — and reducing the need for additional surgeries and steroid courses by 92% in trials.
Updated May 29
Leading developer of DB-OTO gene therapy, seeking FDA approval
Children born profoundly deaf can now hear their parents' voices. A single injection of gene therapy into the inner ear restored hearing in dozens of patients, moving genetic deafness from permanent disability to treatable condition. The effect is rapid—most patients recover hearing within weeks and retain it for at least two years.
Updated May 19
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
